Sponsored by:

Radiopharmaceutical Therapy Tracker

Mar 30, 2026
Rt Tracker

To help keep up with the dynamic landscape in nuclear medicine fueled by theranostics, AuntMinnie offers the Radiopharmaceutical Therapy (RPT) Tracker. Reach us at [email protected] with new entries or updates.

Last Updated: July 15, 2026 ↓
Latest News: July 15, 2026 ▾
Company Drug (Isotope) / Imaging Agent Indication(s) / Target Phase
Latest in Nuclear Medicine
Prostate Imaging
Lutetium-177 PSMA-617 shows promise in earlier-stage prostate cancer
July 21, 2026
Advancing molecular imaging together
Sponsored
Advancing molecular imaging together
May 24, 2026
Cash Bills
AdvanCell raises $315M for targeted alpha therapy
July 15, 2026
Artificial Intelligence Ai 400
Nucs AI, Segmed to build AI validation platform for theranostics
July 14, 2026
Related Stories
Cash Bills
Nuclear Medicine
AdvanCell raises $315M for targeted alpha therapy
Radiation Therapy Planning 400 (3)
Radiation Oncology/Therapy
Radnostix acquires Lara System, Ellexa software from Lucerno
Nuclearmedicine
Nuclear Medicine
AdvanCell establishes U.S. headquarters, manufacturing facility
Advancing molecular imaging together
Sponsor Content
Advancing molecular imaging together
More in Nuclear Medicine
Lutetium-177 PSMA-617 shows promise in earlier-stage prostate cancer
By Will Morton
Across 14 studies, PSA50 response rates (the number of patients with at least a 50% drop in PSA) ranged from 44% to 100%.
July 21, 2026
Prostate Imaging
GE HealthCare introduces MIM Anyware remote access platform
By AuntMinnie.com staff writers
The platform allows authorized users to access MIM software applications from any location without local installation.
July 21, 2026
Ge Health Care Logo
AdvanCell raises $315M for targeted alpha therapy
By AuntMinnie.com staff writers
The company is developing ADVC001, a lead-212 (Pb-212)-based targeted alpha therapy for metastatic prostate cancer.
July 15, 2026
Cash Bills
Nucs AI, Segmed to build AI validation platform for theranostics
By AuntMinnie.com staff writers
The companies will develop disease-specific registries, curated research cohorts, and validation frameworks.
July 14, 2026
Artificial Intelligence Ai 400
Actineer completes Ra-226 recycling process to support Ac-225 supply
By AuntMinnie.com staff writers
This process aims to improve Ac-225 supply predictability and cost stability, as well as reduce waste generation.
July 14, 2026
Nuclear Medicine Worker Sm
Molecular Partners, Orano Med dose first patients in MP0712 trial
By AuntMinnie.com staff writers
MP0712 is a designed ankyrin repeat protein (DARPin) that targets delta-like ligand 3 (DLL3).
July 2, 2026
Nuclear Medicine
RefleXion Medical submits FDA 510(k) for Anchor Point tumor tracking
By AuntMinnie.com staff writers
RefleXion Medical is seeking FDA clearance for the company's Anchor Point Tracking tech for radiotherapy use.
June 30, 2026
Anchor Point Tracking, designed for use with the new RefleXion X2 platform, underpins SCINTIX therapy with higher fidelity biologic data.
Ratio Therapeutics signs Ac-225 supply agreement with PanTera
By AuntMinnie.com staff writers
Deal will support Ratio's alpha therapy programs.
June 30, 2026
Business Deal Corporate 400
SNMMI mourns passing of Twyla Bartel
By AuntMinnie.com staff writers
The SNMMI is mourning the passing of one of its leading members.
June 23, 2026
Twyla Bartel, DO
AdvanCell establishes U.S. headquarters, manufacturing facility
By AuntMinnie.com staff writers
The Andover site will support development and future commercialization of ADVC001.
June 22, 2026
Nuclearmedicine
New immuno-PET tracer shows promise in prostate cancer
By Will Morton
Compared to conventional imaging, Zr-89 DFO-YS5 PET identified additional lesions.
June 15, 2026
A 74-year-old patient with metastatic prostate cancer with a positive left iliac wing lesion (SUVmax of 35.02) seen on (A) Zr-89 DFO-YS5 PET maximum projection image (MIP) and (B) PET/CT (red arrows). The lesion was graded 5 on PET but was not visible on CT (D) or (D) technitium-99 MDP bone scan.
What side effects do patients report after Pluvicto therapy?
By Will Morton
Fatigue, pain flare, nausea, and urinary symptoms are among the most commonly reported immediate side effects of Pluvicto therapy.
June 5, 2026
Post-Pluvicto SPECT/CT with axial fused images of sacrum and sagittal maximum intensity projection of one of the patients who complained of increasing pain in the sacral region (arrows) post therapy.
Page 1 of 444
Next Page